Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study브라질에서 2회 용량 1차 프로토콜 및 BNT162b2 이종 부스터(Immunita-001)에서 비활성화된 바이러스(CoronaVac) 백신의 면역원성, 효과 및 안전성: 1년 기간의 후속 조치 4상 연구Clinical Trial Published on 2022-06-092022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody antibody antibody levels Antibody titer Antibody titers approach association BNT162b2 booster booster dose Brazil Cellular immune response chemokines CoronaVac coronavirus COVID-19 COVID-19 pandemic Critical Cytokines Delta delta variant dose Effectiveness exposure to followed by growth factor Growth factors Heterologous heterologous booster highest IgG immune Immune profile immune response immunogenicity implication individual individuals Interaction maintenance male median mediators Neutralising Antibodies neutralising antibody no increase omicron Omicron variant pandemic Period phase 4 presenting protocol reduction remained respiratory restored robust Safe Safety SARS-CoV-2 Seropositivity severe acute respiratory syndrome Coronavirus significantly Spread timepoint titer titers vaccination Vaccine variant virus Year [DOI] 10.3389/fimmu.2022.918896 PMC 바로가기 [Article Type] Clinical Trial
IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational studySARS-CoV-2 백신 접종 후 6개월까지 IgG 항체 생성 및 지속성: 북아일랜드 관찰 연구Observational Study Published on 2022-04-202022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Adenovirus Adenovirus vector-based vaccine Anti-spike antibody Antibody Response ChAdOx1 clinically collected COVID-19 COVID-19 vaccination detectable dose evaluate first vaccination FIVE IgG antibody IgG response IgG responses individual Ireland Lateral flow device majority Oxford-AstraZeneca Oxford-AstraZeneca ChAdOx1 participant persistence plasma samples pre-vaccination Protein receive rising Sample SARS-CoV-2 second dose significantly higher Spike protein timepoint timepoints Vaccine vaccine dose [DOI] 10.1016/j.vaccine.2022.02.087 PMC 바로가기 [Article Type] Observational Study
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort studyObservational Study Published on 2022-03-012022-10-05 Journal: The Lancet. Healthy longevity [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] Abstract Administered administration age anti-RBD Anti-RBD IgG anti-Spike IgG Anti-spike IgG responses antibody Antibody Response antigenicity automated baseline binding antibody unit blood sample BNT162b2 BNT162b2 vaccine boost Canada Care clinical clinically Cohort cohorts collected combinations Comorbidity Concentration COVID-19 COVID-19 mRNA Vaccination COVID-19 vaccine decrease distribution dose doses Effectiveness eligible ELISA enrolled extended-interval first dose fluctuation for inclusion force French Government Heterologous heterologous prime-boost homologous or heterologous individual infected individual Interim Interim report log material Moderna mRNA vaccine mRNA vaccines mRNA-1273 mRNA-1273 vaccine mRNA-based COVID-19 vaccine nucleocapsid protein of BNT162b2 Older participant Participants Pfizer-BioNTech prime and boost prospective observational cohort PROTECT Public reference response SARS-COV-2 infection SARS-CoV-2-specific IgG second dose serological response service significant difference significant increase tested the receptor-binding domain the spike protein timepoint translation Trimeric spike protein university Vaccine vaccine availability vaccine dose Vaccines was done were used [DOI] 10.1016/S2666-7568(22)00012-5 PMC 바로가기 [Article Type] Observational Study
Resilience to COVID-19: Socioeconomic Disadvantage Associated With Positive Caregiver–Youth Communication and Youth Preventative ActionsPublic Health Published on 2022-02-092022-10-31 Journal: Frontiers in Public Health [Category] COVID-19, COVID19(2023년), MERS, SARS, [키워드] Action Adolescence Adolescent Caregivers collected communication COVID-19 COVID-19 disease COVID-19 infection development disadvantage disease distress emotional family greater highlight impacts less likelihood pandemic Protective reduce response risk Socioeconomic Factors timepoint Youth [DOI] 10.3389/fpubh.2022.734308 PMC 바로가기 [Article Type] Public Health
Physical Activity, Mental Health and Wellbeing of Adults within and during the Easing of COVID-19 Restrictions, in the United Kingdom and New ZealandArticle Published on 2022-02-042022-10-29 Journal: International Journal of Environmental Research an [Category] Coronavirus, COVID19(2023년), MERS, SARS, [키워드] activity association coronavirus disease COVID-19 COVID-19 pandemic Depression exercise Health index individual initial lifestyle behaviour change lockdown measure mental health moderate New no difference pandemic Participation reduced significantly timepoint United Kingdom Volume [DOI] 10.3390/ijerph19031792 PMC 바로가기 [Article Type] Article
Immune interventions in COVID-19: a matter of time?COVID-19에 대한 면역 개입: 시간 문제입니까?Review Published on 2022-02-012022-09-11 Journal: Mucosal Immunology [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] administration animal model animal models Antiviral strategies antiviral strategy available data beta-coronavirus clinical trial clinical trials COVID-19 pandemic discrepancies dysregulated immune response Effect effective Efficacy Frame heterogeneity hyperinflammation immune immune response immunosuppressive drug Infection infections Intervention Kinetics lack Patient Pneumonia reactive required severe COVID-19 the timing Time frame timepoint tissue lesion tissue lesions Treatment [DOI] 10.1038/s41385-021-00464-w PMC 바로가기 [Article Type] Review
ICU admission and mortality classifiers for COVID-19 patients based on subgroups of dynamically associated profiles across multiple timepoints여러 시점에 걸쳐 동적으로 연결된 프로필의 하위 그룹을 기반으로 하는 COVID-19 환자에 대한 ICU 입원 및 사망률 분류기Article Published on 2022-02-012022-09-11 Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 바이오마커, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus ALP among others Analysis association automated Bayesian Biomarker Biomarkers caused Classifier classifiers Clinical data Cluster Clustering analysis Clusters coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients data curation Disease progression dynamic Dynamic Bayesian Networks (DBNs) ENhance feature FiO2 global healthcare group homogeneous ICU ICU admission identify information knowledge LDH Lymphocytes Map Mortality network neutrophil Neutrophils patient subgroup profile profiles risk factor Risk factors robust SARS-CoV-2 self Self-Organizing Maps (SOMs). sensitivity Sensitivity and specificity specificity subgroup timepoint trajectory Trajectory analysis Transmissibility unmet need yielding [DOI] 10.1016/j.compbiomed.2021.105176 PMC 바로가기 [Article Type] Article
Critical Periods, Critical Time Points and Day-of-the-Week Effects in COVID-19 Surveillance Data: An Example in Middlesex County, Massachusetts, USAArticle Published on 2022-01-252022-10-30 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] adaptive center change changes in COVID-19 Critical data reliability day-of-the-week effects death defined Department described Effect effect size Engineering examined fluctuation had no Health authority healthcare Intervention Kolmogorov-Zurbenko filters Laboratory testing less Massachusett Massachusetts Monday Nonpharmaceutical interventions Novel coronavirus outbreak pandemic Point Precision public health preferences protocols Public reported Repository SARS-CoV-2 surveillance SARS-CoV-2 testing Science stringency Surveillance System time timepoint Tuesday understanding USA [DOI] 10.3390/ijerph19031321 PMC 바로가기 [Article Type] Article
Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)SARS-COV-2 호주 성인 및 암 소아에서의 산후 감시 연구 프로토콜 : SARS-COV-2 백신 접종 (Seroznet)에 대한 안전 및 혈청 학적 및 면역 학적 반응에 대한 관찰 연구 (Seroznet)Study Protocol Published on 2022-01-202022-09-10 Journal: BMC Infectious Diseases [Category] SARS, 변종, 임상, [키워드] acceptability adverse event adverse events allergy Analysis Blood Cancer Cancer patients Characteristics Chemotherapy children clinical clinical trial clinical trials cohorts collected commenced comparable condition controls coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 vaccinations COVID-19 vaccine COVID-19 vaccines disease manifestation effective enrolled exploration FIVE haematological malignancy healthy healthy control healthy controls HM patient HM patients hypogammaglobulinaemia Immune checkpoint inhibitor Immune checkpoint inhibitors immune correlate immune correlates immune response Immunity Immunocompromise Immunological response Immunosuppression immunosuppressive condition immunosuppressive conditions incidence Infection less life malignancy morbidity and mortality naïve New observational study organ pandemic coronavirus Patient Patients with cancer peripheral Peripheral blood Polysorbate polysorbate 80 populations Post-vaccine pre-vaccination processed proportion prospective observational study Quality question receiving reducing Registered Registration registry reported required robust SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Serologic response serologic responses serological serological response severe COVID-19 SOC solid organ supplementary material Surveillance systemic therapy T-cell therapy timepoint Toxicity Treatment Trial unique vaccination Vaccinations Vaccine Vaccine hesitancy vaccine response variants virus were excluded [DOI] 10.1186/s12879-021-07019-1 PMC 바로가기 [Article Type] Study Protocol
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts교차 반응성 기억 T 세포는 COVID-19 접촉에서 SARS-CoV-2 감염에 대한 보호와 관련이 있습니다Article Published on 2022-01-102022-09-10 Journal: Nature Communications [Category] 진단, 치료기술, 치료법, [키워드] Antigen Antimicrobial responses Cohort Contact contact with contribute coronavirus Coronaviruses COVID-19 cross-react cross-reactive Cross-reactive immune responses cytokine Donor dual Endemic Epitopes Evidence Frequency Host household contact human coronavirus immune response immune responses Immunity Immunological memory Inclusion Infection infection rate membrane memory T cell memory T cells mononuclear cells no significant difference nucleocapsid observé ORF1 PCR-negative PCR-positive Peripheral blood Peripheral blood mononuclear cells Protective remained response SARS-CoV-2 SARS-CoV-2 epitope SARS-COV-2 infection significant difference T cell T cells timepoint Vaccines viral infection while [DOI] 10.1038/s41467-021-27674-x PMC 바로가기 [Article Type] Article